ClinicalTrials.gg
RecruitingNCT06610799Updated Nov 20, 2024

Study of IBI363 in Patients with Advanced First-line Gastric Cancer

A Phase 1 interventional study of IBI363 in IBI363 + Chemotherapy, sponsored by Xiangdong Cheng. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Xiangdong Cheng · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.

02

Conditions studied

  • IBI363 + Chemotherapy
03

In context

Lead sponsor

Xiangdong Cheng is the lead sponsor of 7 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, ≥ 18 years and ≤75 years.
  2. Subjects with unresectable advanced or gastric and gastroesophageal junction adenocarcinoma without prior systematic treatment.
  3. Subjects with at least one according to v1.1.
  4. performance status (ECOG PS) of 0 or 1.
  5. Expected survival time ≥ 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug.
  2. Active uncontrolled bleeding or a known bleeding diathesis.
  3. Subjects with history of or known active seizure disorder, , spinal cord compression, or carcinomatous meningitis, or new evidence of brain or .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    IBI363 combination with oxaliplatin and capecitabine (XELOX) for first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma

    Drug: IBI363

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The efficacy of solid tumors was evaluated according to RECIST v1.1

    Time frame: Through out the study (up to 2 years)

  2. Disease control rate (DCR)

    The efficacy of solid tumors was evaluated according to RECIST v1.1

    Time frame: Through out the study (up to 2 years)

Secondary outcomes

  1. Progression Free Survival(PFS);

    The efficacy of solid tumors was evaluated according to RECIST v1.1

    Time frame: Up to 2 years

  2. Overall Survival, OS)

    The efficacy of solid tumors was evaluated according to RECIST v1.1

    Time frame: Up to 2 years

  3. Adverse Enent (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0.

    Time frame: Up to 90 days after the last administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Jun 2025, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Sep 24, 2024
StartActual
Oct 15, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2026
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06610799
Lead sponsor
Xiangdong Cheng
Responsible party
Xiangdong Cheng (Secretary of the party committee, Zhejiang Cancer Hospital) — Sponsor-investigator
First posted
Sep 24, 2024
Start date
Oct 15, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 20, 2024

Study contacts

Yanxi Pu
Contact
yanxi.pu@innoventbio.com
18523197816

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Start the discussion